Full Text View
Tabular View
No Study Results Posted
Related Studies
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)
This study is ongoing, but not recruiting participants.
First Received: September 20, 2007   Last Updated: March 26, 2009   History of Changes
Sponsored by: AstraZeneca
Information provided by: AstraZeneca
ClinicalTrials.gov Identifier: NCT00532922
  Purpose

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.


Condition Phase
Asthma
 Phase IV

MedlinePlus related topics: Asthma
Drug Information available for: Symbicort
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Further study details as provided by AstraZeneca:

Biospecimen Retention:   None Retained

Biospecimen Description:

Enrollment: 310
Study Start Date: April 2007
Groups/Cohorts
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Natural History, longitudinal, defined population

Criteria

Inclusion Criteria:

  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532922

Locations
China
Research Site
Shanghai, China
Research Site
Chongqing, China
Research Site
Beijing, China
Research Site
Hangzhou, China
China, Anhui
Research Site
Hefel, Anhui, China
China, Fujian
Research Site
Fuzhou, Fujian, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
China, Henan
Research Site
Zhengzhou, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Hubel
Research Site
Wuhan, Hubel, China
China, Jiangsu
Research Site
Suzhou, Jiangsu, China
Research Site
Nanjong, Jiangsu, China
China, Liaoning
Research Site
Shenyand, Liaoning, China
China, Shandong
Research Site
Qingdao, Shandong, China
China, Shanxi
Research Site
Xi'an, Shanxi, China
Research Site
Taiyuan, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Wenzhou, Zhejiang, China
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Zhou Xin Shanghai First People's Hospital
Principal Investigator: Hong Jianguo Shanghai First People's Hospital
  More Information

No publications provided

Study ID Numbers: NIS-RCN-SYM-2006/1
Study First Received: September 20, 2007
Last Updated: March 26, 2009
ClinicalTrials.gov Identifier: NCT00532922     History of Changes
Health Authority: Not required for this study:

Study placed in the following topic categories:
Symbicort
Anti-Asthmatic Agents
Asthma

Additional relevant MeSH terms:
Respiratory System Agents
Symbicort
Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 07, 2009



U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services